Visit Endo.com

High value branded pharmaceutical products.

Explore EndoPharma.com

Treatments for today’s unmet pelvic health needs.

Explore VisitAMS.com

Affordable, high-quality generic pharmaceuticals.

Explore QualitestRx.com

Pharmaceutical products for Canadian & emerging markets.

Explore Paladin Labs

Completed Clinical Trial and Study Results

Endo is committed to supporting transparent and responsible scientific disclosure regarding its clinical studies. To that end, Endo registers all Applicable Clinical Trials on clinicaltrials.gov, provides status updates, and is transparent about study results. Endo also posts study results of additional Endo-sponsored studies on this website, which can be viewed in the attached files.

For results on completed clinical trials that have been sponsored by Endo, please go to www.clinicaltrials.gov or follow the links provided below. Results for Postmarketing Commitment and Requirement studies are posted on the Postmarketing Commitments and Requirements webpage.

Study ID	Study Description	Study Treatment	Clinical Study Results
303	Vantas Implant Retrieval Study	VANTAS® (histrelin acetate) subcutaneous implant	NCT01013025
AUX-CC-802	A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 X 4) In Men With Peyronie's Disease	XIAFLEX® (collagenase clostridium histolyticum)	NCT01243411
AUX-CC-806	A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for Up to Four Treatment Cycles (2 X 4) In Men With Peyronie's Disease	XIAFLEX® (collagenase clostridium histolyticum)	NCT01685437
AUX-CC-807	A phase 3b, open-label pilot study to evaluate the safety and effectiveness of up to four treatment cycles of AA4500 in combination with the ErecAid® Esteem® Manual Vacuum Therapy System in men with Peyronie’s disease	XIAPEX® (AA4500 [collagenase clostridium histolyticum])	EudraCT 2013-005384-66
AUX-CC-831	A Phase 2, Randomized, Double-blind, Placebo-Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy	Collagenase clostridium histolyticum (CCH)	NCT01987986
AUX-CC-860 Year 5	Year 5 Final Annual Report of A Long-Term Follow-Up of Subjects Treated With AA4500 in Studies AUX-CC-854, AUX-CC-856, AUX-CC-857/AUX-CC-858, and AUX-CC-859	XIAFLEX® (collagenase clostridium histolyticum)	NCT00954746
AUX-CC-862	Retreatment of Recurrent Contractures in Joints Effectively Treated with AA4500 (Collagenase Clostridium Histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-Sponsored Phase 3 Study in the United States, Australia, and Europe	XIAFLEX® (collagenase clostridium histolyticum)	NCT01498640
AUX-CC-864	An open-label study to assess the safety and efficacy of concurrent administration of two injections of AA4500 0.58 mg into the same hand of subjects with multiple Dupuytren's contractures	XIAFLEX® (collagenase clostridium histolyticum)	NCT01407068
AUX-CC-901	COmmunity RegistRy Study Evaluating Dupuytren’s Contracture Treatment: A Prospective, Observational, Longitudinal, Multicenter Study of Treatment Patterns and Outcomes in Patients with Dupuytren's Contracture	XIAFLEX® (collagenase clostridium histolyticum)	NCT01715467
AUX-CC-902	A multicenter observational study of the real life effectiveness and safety of Xiapex® in the treatment of Dupuytren's disease in Belgium	XIAFLEX®/XIAPEX® (collagenase clostridium histolyticum)
EN3202-012	Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy, Opioid Dose Sparing Effects and Safety of Controlled Release Oxymorphone and Placebo in Patients with Postsurgical Pain Following Knee Arthroplasty	Oxymorphone controlled-release tablets
EN3202-015	Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release Oxymorphone, Controlled Release Oxycodone (OxyContin®) and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip	Oxymorphone controlled-release tablets
EN3202-016	Evaluation of the Efficacy and Safety of Numorphan® CR (Oxymorphone HCl Controlled Release) Relative to Placebo and OxyContin® (Oxycodone HCl Controlled Release) in Subjects with Chronic Low Back Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-017	Open Label, Sequential Crossover Evaluation of the Analgesic Dose Equivalence, Efficacy and Safety of Controlled-Release Oxymorphone (Numorphan® CR) Relative to Controlled-Release Oxycodone (OxyContin®) and Controlled-Release Morphine (MS Contin®) in Patients With Cancer Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-018	A Randomized, Double-Blind, Two-Period Crossover Trial Comparing the Safety and Effectiveness of Numorphan® CR (oxymorphone controlled-release tablets) and MS Contin® (morphine sulfate controlled release tablets) for the Relief of Moderate to Severe Pain in Patients with Cancer	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-019	A Randomized, Double-Blind, Two-Period Crossover Study Comparing the Efficacy, Safety and Tolerability of Numorphan® CR (Oxymorphone HCl, Controlled Release) and OxyContin® (Oxycodone HCl, Controlled Release) in Cancer Patients Who Require Chronic Opioid Treatments	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-020	A Multicenter, Open Label Extension Study to Evaluate the Long-term Safety and Effectiveness of Numorphan® CR in Patients with Chronic Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-021	An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy of Numorphan® CR (oxymorphone HCl controlled release) in Subjects With Cancer Pain or Chronic Lower Back Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00904280
EN3202-022	An Open-Label Assessment of the Long-Term Safety and Utility of Numorphan® CR for the Relief of Moderate to Severe Pain in Patients with Cancer	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00904449
EN3202-025	Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy and Safety of Extended Release Oxymorphone and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3202-028	Safety and Efficacy Study of Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00911287
EN3202-029	Long-term Effectiveness and Safety Study of Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00911261
EN3202-031	Efficacy and Safety of Oxmorphone Extended Release in Opioid-Naive Patients with Chronic Low Back Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00225797
EN3202-032	Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Low Back Pain	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00226421
EN3202-402	Study to Compare Subjective and Objective Effects of Oxymorphone Extended-Release (OPANA ER) Versus Oxycodone Controlled-Release (OxyContin)	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets	NCT00955110
EN3203-004	Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Comparison of the Analgesic Efficacy and Safety of Numorphan® IR (Oxymorphone HCl Immediate Release), Percolone, and Placebo in Patients With Postsurgical Pain Following Orthopedic Total Hip and Knee Replacement	Oxymorphone hydrochloride immediate-release tablets
EN3203-005	A Multicenter, Randomized, Double-Blind, Placebo and Active Controls, Single-Dose Study of Oxymorphone IR and Oxycodone IR in Patients With Pain Following Orthopedic Surgery.	Oxymorphone hydrochloride immediate-release tablets
EN3203-008	Post-operative Knee Surgery Efficacy and Safety Study	OPANA® (oxymorphone hydrochloride) Tablets	NCT00904085
EN3203-009	Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain	OPANA® (oxymorphone hydrochloride) Tablets	NCT00226395
EN3220-006	Open-label Efficacy Study of Topical Lidocaine Patch in Low Back Pain	LIDODERM® (Lidocaine Patch 5%)	NCT00904540
EN3220-008	A Study of the Effectiveness and Safety of Lidoderm® as Add-on Treatment in Patients with Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain	LIDODERM® (Lidocaine Patch 5%)	NCT00904020
EN3220-009	A Study of Lidocaine Patch 5% Alone, Gabapentin Alone, and Lidocaine Patch 5% and Gabapentin in Combination for the Relief of Pain in Patients with Diverse Peripheral Neuropathic Pain Conditions	LIDODERM® (Lidocaine Patch 5%)	NCT00904202
EN3220-011	Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain	LIDODERM® (Lidocaine Patch 5%)	NCT00904475
EN3220-012	Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee	LIDODERM® (Lidocaine Patch 5%)	NCT00904605
EN3220-013	Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain	LIDODERM® (Lidocaine Patch 5%)	NCT00904397
EN3225-001	Open-Label Pilot Study Assessing the Efficacy and Safety of New Formulations of Percocet® in the Treatment of Low Back Pain	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3225-002	A Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Study of the Safety and Efficacy of Low-dose Percocet® Compared to OxyContin® in Patients With Acute Pain Following Third Molar Extraction	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3225-003	A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of the Safety and Efficacy of Low-Dose Percocet® in Patients With Acute Pain Following Third Molar Extraction	PERCOCET® (oxycodone hydrochloride and acetaminophen USP) Tablets
EN3260-001	Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee	LIDODERM® (Lidocaine Patch 5%)	NCT00904462
EN3260-003	Efficacy and Safety of the Lidoderm Patch 5% Applied to Patients With Osteoarthritis of the Knee	LIDODERM® (Lidocaine Patch 5%)	NCT00589979
EN3261-001	A Study Comparing the Efficacy and Safety of Lidocaine 5% Patch With Placebo in Patients With Chronic Axial Low Back Pain	LIDODERM® (Lidocaine Patch 5%)	NCT00904111
EN3266-401	Effectiveness and Safety of Frovatriptan for the Management (Acute Treatment) of Menstrual Migraine	FROVA® (frovatriptan succinate) Tablets	NCT00904098
EN3272-301	Safety and Efficacy Study of Lidoderm (Lidocaine Patch 5%) Compared with Placebo in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome	LIDODERM® (Lidocaine Patch 5%)	NCT00266214
EN3288-108	An Open-Label, Randomized, Single-Dose, Six Period, Crossover Study to Evaluate the Relative Bioavailability of EN3288 40 mg Intact and After Physical Tampering Using Various Methods Compared with OPANA® 10 mg (4 × 10 mg) in Healthy Adult Subjects	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3288-109	A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Crossover Study to Evaluate the Relative Bioavailability and Subjective Effects of EN3288 40 mg Administered Intact and After Mastication Compared With OPANA® ER 40 mg Administered After Mastication and With OPANA® 40 mg (4 × 10 mg) Administered Intact in Healthy Non-Dependent Recreational Oral Prescription Opioid Users Experienced in Mastication of Extended-Release Opioid Formulations	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3288-113	A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who Recreationally Administer Opioids Intranasally	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3288-114	A Randomized Double-Blind, Single-Dose, Placebo-Controlled, Four-Period, Crossover Study to Evaluate the Subjective Effects and Systemic Exposure of Manipulated OPANA® ER Administered Intranasally Compared with Oxymorphone Hydrochloride Powder Administered Intranasally in Healthy, Non-Dependent Subjects Who Recreationally Administer Opioids Intranasally	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3288-901	Assessment of the ease with which experienced controlled-release prescription opioid abusers prepare a tamper-resistant formulation for intravenous use: comparison between OPANA® ER and oxymorphone HCl extended-release tamper-resistant tablets	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3288-902	Assessment of the ease with which experienced controlled-release prescription opioid abusers prepare a tamper-resistant formulation for intranasal use: comparison between OPANA® ER and oxymorphone HCl extended-release tamper-resistant tablets	OPANA® ER (oxymorphone hydrochloride) Extended-Release Tablets
EN3319-301	Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects	Oxymorphone hydrochloride immediate-release oral liquid	study terminated NCT01206907
EN3326-300 Former 03-CPP-HIS-300	Phase III Efficacy and Safety Study of Histrelin Subcutaneous Implant in Children With Central Precocious Puberty	SUPPRELIN® LA (histrelin acetate) subcutaneous implant	NCT00779103
EN3329-A9301/A9302	Intravesical AD 32 (valrubicin) in Patients With Carcinoma In Situ of the Bladder Who Have Failed or Have Recurrence Following Treatment with Bacillus Calmette-guerin (BCG)	Valstar® (valrubicin) Sterile Solution	NCT01316874
EN3330-301	Phase III Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer	Vantas® (histrelin acetate) subcutaneous implant
EN3330-302	Phase III Study of Histrelin Subdermal Implant in Patients With Advanced Metastatic Prostate Cancer	Vantas® (histrelin acetate) subcutaneous implant
EN3835-201	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy	Collagenase clostridium histolyticum (CCH)	NCT02724644
FOR01C	A Study of Fortigel Testosterone Gel 2% in Males With Low Testosterone	FORTESTA® (testosterone) Gel	NCT00522431
IP157-001	Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men	AVEED® (testosterone undecanoate) injection	NCT00467870
IP157-003	Phase I, Double-Blind Study to Evaluate the Allergic Potential of NEBIDO® and Formulation Components in Patients Who Have Exhibited Anaphylactic-Like Reactions Following Intramuscular Injection of NEBIDO®	NEBIDO® (testosterone undecanoate)* *Bayer Pharma AG
VML 251-3MRM02	A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine	FROVA® (frovatriptan succinate) Tablets	NCT00475514
VML 251-3MAM03	Safety and Tolerability of Frovatriptan in Prevention of Menstrually Associated Migraine (MAM) Headaches	FROVA® (frovatriptan succinate) Tablets	NCT01035983

By clicking on the link(s) on this page you will leave the Endo.com website and move to an external website(s) independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website(s) you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.

About Endo

Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.

Visit Endo.com